secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078116
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial
--------------------------------------------------------------

- Cash and equivalents total $1.03M as of June 30, 2025.
- Net loss per share improved to $0.34 from $0.60 YoY.
- G&A expenses fell to $1.4M from $2.1M; R&D rose to $1.1M from $0.9M.
- FDA cleared Phase 3b ENDURANCE trial targeting ~200 ALS patients.
- Signed LOI with CDMO Minaris for NurOwn manufacturing for the trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/0001104659-25-078116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/tm2523508d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer